The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic partnership with Sanofi (NASDAQ: SNY) to develop and commercialize a groundbreaking 9-valent vaccine targeting extraintestinal pathogenic Escherichia coli (ExPEC). Currently in late-stage trials, this vaccine aims to prevent invasive E. coli disease (IED) in adults aged 60 years and older.
Financial Terms and Collaborative Efforts
Under the terms of the agreement, Sanofi will co-fund the development program, providing Janssen with an upfront payment of USD 175 million. The partnership also includes milestone payments and royalties for most global markets. Notably, in France, Germany, Italy, Spain, the UK, and the US, the companies will share profits, reflecting a collaborative approach to maximize the vaccine’s reach.
Significance of Invasive E. coli Disease
Invasive E. coli disease affects nearly 10 million adults annually, arising when intestinal bacteria spread to other organs, potentially resulting in severe complications such as blood infections and sepsis. This partnership underscores both companies’ commitment to addressing significant public health challenges through innovative vaccine development.-Fineline Info & Tech
